SW209049

CAS No. 1673558-59-2

SW209049( —— )

Catalog No. M37687 CAS No. 1673558-59-2

SW209049 is a stearoyl-CoA 9-desaturase inhibitor. SW209049 exhivits potent activity against H2122 cell with IC50 of 0.13uM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 170 In Stock
5MG 153 In Stock
10MG 225 In Stock
25MG 337 In Stock
50MG 465 In Stock
100MG 625 In Stock
200MG 828 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SW209049
  • Note
    Research use only, not for human use.
  • Brief Description
    SW209049 is a stearoyl-CoA 9-desaturase inhibitor. SW209049 exhivits potent activity against H2122 cell with IC50 of 0.13uM.
  • Description
    SW209049 is a stearoyl-CoA 9-desaturase inhibitor. SW209049 exhivits potent activity against H2122 cell with IC50 of 0.13uM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Dehydrogenase
  • Recptor
    Dehydrogenase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1673558-59-2
  • Formula Weight
    442.49
  • Molecular Formula
    C25H18N2O4S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N(C(=O)C1=CC=C(C(=O)C2=CC=C(OCC#C)C=C2)C=C1)C3=NC=4C(S3)=CC(OC)=CC4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • AG-636

    AG-636 is a potent, reversible, selective and orally active DHODH inhibitor(IC50 of 17 nM). It has strong anticancer effects.

  • 17β-HSD10-IN-1

    17β-HSD10-IN-1 is an orally available 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) inhibitor with blood-brain permeability and potency for the study of Alzheimer's disease.

  • JC2-11

    JC2-11 is an inhibitory compound for inflammation.JC2-11 inhibits the recruitment domain-containing proteins NLRC 4, atypical in melanoma 2 (AIM 2) and atypical (NC) inflammatory vesicles by disrupting reactive oxygen species (ROS) production and caspase-1 activity.